Table of Contents Author Guidelines Submit a Manuscript
Advances in Pharmacological Sciences
Volume 2013, Article ID 313858, 8 pages
http://dx.doi.org/10.1155/2013/313858
Review Article

Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis

1Department of Health Science, School of Medicine, University of Catanzaro, Viale Europa, 88100 Catanzaro, Italy
2Pharmacovigilance's Center Regione Calabria, University Hospital Mater Domini, 88100 Catanzaro, Italy
3Rheumatology Research Unit and Ph.D. Program in Molecular Oncology, Experimental Immunology and Development of Innovative Therapies, University of Catanzaro, 88100 Catanzaro, Italy

Received 17 March 2013; Revised 9 April 2013; Accepted 16 April 2013

Academic Editor: Raymond M. Quock

Copyright © 2013 Marinella Patanè et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Tambar and E. M. Ruderman, “Current management of rheumatoid arthritis,” Managed Care Interface, vol. 20, no. 7, pp. 18–24, 2007. View at Google Scholar
  2. S. De Fazio, L. Gallelli, P. Gareri, D. Mazzotta, P. A. Rende, and G. De Sarro, “Pharmacological properties of nonsteroideal anti-inflammatory drugs: a review,” Current Topics in Pharmacology, vol. 13, no. 1, pp. 75–83, 2009. View at Google Scholar · View at Scopus
  3. L. Gallelli, O. Galasso, A. Urzino et al., “Characteristics and clinical implications of the pharmacokinetic profile of ibuprofen in patients with knee osteoarthritis,” Clinical Drug Investigation, vol. 32, pp. 827–833, 2012. View at Google Scholar
  4. F. Oliva and L. Gallelli, “Ibuprofen pharmacology and its implications for musculoskeletal disorders,” Functional Neurology, vol. 25, no. 3, supplement 1, pp. 1–19, 2010. View at Google Scholar · View at Scopus
  5. L. Gallelli, M. Colosimo, D. Pirritano et al., “Retrospective evaluation of adverse drug reactions induced by nonsteroidal anti-inflammatory drugs,” Clinical Drug Investigation, vol. 27, no. 2, pp. 115–122, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. W. Bijlsma, “Disease control with glucocorticoid therapy in rheumatoid arthritis,” Rheumatology, vol. 51, supplement 4, pp. 9–13, 2012. View at Google Scholar
  7. M. Boers, “Prednisone for rheumatoid arthritis: the detriment of the doubt,” Nederlands Tijdschrift voor Geneeskunde, vol. 155, no. 32, p. A5069, 2012. View at Google Scholar
  8. L. Clarke and J. Kirwan, “Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis,” Therapeutic Advances in Musculoskeletal Disease, vol. 4, no. 3, pp. 159–166, 2012. View at Google Scholar
  9. G. Haugeberg, A. Strand, T. K. Kvien, and J. R. Kirwan, “Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial,” Archives of Internal Medicine, vol. 165, no. 11, pp. 1293–1297, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Makrygiannakis, S. Revu, M. Engstrom et al., “Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis,” Arthritis Research & Therapy, vol. 14, no. 1, p. R20, 2012. View at Google Scholar
  11. E. McKeown, V. P. Bykerk, F. De Leon et al., “CATCH Investigators. Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort,” Rheumatology, vol. 51, no. 9, pp. 1662–1669, 2012. View at Google Scholar
  12. C. Montecucco, M. Todoerti, G. Sakellariou, C. A. Scirè, and R. Caporali, “Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study,” Arthritis Research & Therapy, vol. 14, no. 3, p. R112, 2012. View at Google Scholar
  13. J. R. O'Dell, “Therapeutic strategies for rheumatoid arthritis,” The New England Journal of Medicine, vol. 350, no. 25, pp. 2591–2630, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. R. A. Quax, J. W. Koper, P. H. de Jong et al., “In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis,” Arthritis Research & Therapy, vol. 14, no. 4, p. R195, 2012. View at Google Scholar
  15. D. L. Scott, K. Pugner, K. Kaarela et al., “The links between joint damage and disability in rheumatoid arthritis,” Rheumatology, vol. 39, no. 2, pp. 122–132, 2000. View at Google Scholar · View at Scopus
  16. U. Baschant, N. E. Lane, and J. Tuckermann, “The multiple facets of glucocorticoid action in rheumatoid arthritis,” Nature Reviews Rheumatology, vol. 8, no. 11, pp. 645–655, 2012. View at Google Scholar
  17. S.-G. Lee, Y.-E. Park, S.-H. Park et al., “Increased frequency of osteoporosis and BMD below the expected range for age among South Korean women with rheumatoid arthritis,” International Journal of Rheumatic Diseases, vol. 15, no. 3, pp. 289–296, 2012. View at Publisher · View at Google Scholar
  18. J. R. Curtis, A. Lanas, A. John, D. A. Johnson, and K. L. Schulman, “Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis,” Arthritis Care & Research, vol. 64, no. 12, pp. 1819–1828, 2012. View at Publisher · View at Google Scholar
  19. J. Zeidler, H. Zeidler, and J. M. Graf von der Schulenburg, “Therapy of rheumatoid arthritis with methotrexate : claims data analysis of treatment patterns,” Zeitschrift für Rheumatologie, vol. 71, no. 10, pp. 900–907, 2012. View at Google Scholar
  20. K. Kruger, J. Wollenhaupt, K. Albrecht et al., “guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm,” Zeitschrift für Rheumatologie, vol. 71, no. 7, pp. 592–603, 2012. View at Google Scholar
  21. A. D. Protogerou, E. Zampeli, and P. P. Sfikakis, “Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis,” Annals of Internal Medicine, vol. 157, no. 4, pp. 299–300, 2012. View at Google Scholar
  22. S. K. Agarwal, “Biologic agents in rheumatoid arthritis: an update for managed care professionals,” Journal of Managed Care Pharmacy, vol. 179, supplement B, pp. S14–S18, 2011. View at Google Scholar
  23. K. G. Saag, G. T. Gim, N. M. Patkar et al., “American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis,” Arthritis Care and Research, vol. 59, no. 6, pp. 762–784, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Gallelli, G. Ferreri, M. Colosimo et al., “Adverse drug reactions to antibiotics observed in two pulmonology divisions of Catanzaro, Italy: a six-year retrospective study,” Pharmacological Research, vol. 46, no. 5, pp. 395–400, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Gallelli, G. Ferreri, M. Colosimo et al., “Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy,” Pharmacological Research, vol. 47, no. 6, pp. 493–499, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Gallelli, V. Guadagnino, B. Caroleo, N. Marigliano, G. B. De Sarro, and A. Izzi, “Bilateral skin ulceration after injection of pegylated interferon-α -2b in a patient with chronic hepatitis C,” Clinical Drug Investigation, vol. 23, no. 9, pp. 615–619, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Gallelli, M. Nardi, T. Prantera et al., “Retrospective analysis of adverse drug reactions induced by gemcitabine treatment in patients with non-small cell lung cancer,” Pharmacological Research, vol. 49, no. 3, pp. 259–263, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Gallelli, V. Guadagnino, B. Caroleo, N. Marigliano, and G. De Sarro, “Cutaneous ulceration induced by interferon alfa,” Annals of Pharmacotherapy, vol. 38, no. 1, pp. 173–174, 2004. View at Google Scholar · View at Scopus
  29. L. Gallelli, S. Del Negro, S. Naty, M. Colosimo, R. Maselli, and G. De Sarro, “Levofloxacin-induced taste perversion, blurred vision and dyspnoea in a young woman,” Clinical Drug Investigation, vol. 24, no. 8, pp. 487–489, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Gareri, L. Gallelli, G. Ferreri Ibbadu, R. Lacava, E. Russo, and G. De Sarro, “Melaena following use of the cholinesterase inhibitor rivastigmine,” Clinical Drug Investigation, vol. 25, no. 3, pp. 215–217, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Gallelli, M. Ferraro, G. F. Mauro, and G. De Sarro, “Generalised dermatitis induced by pegylated interferon-α-2b in a patient infected with genotype-1 hepatitis C virus: presentation of a case,” Clinical Drug Investigation, vol. 25, no. 4, pp. 281–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Gallelli, M. Ferraro, G. F. Mauro, S. De Fazio, and G. De Sarro, “Nimesulide-induced hepatotoxicity in a previously healthy woman,” Clinical Drug Investigation, vol. 25, no. 6, pp. 421–424, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Gallelli, A. Gallelli, G. Vero et al., “Acute renal failure probably induced by prulifloxacin in an elderly woman: a first case report,” Clinical Drug Investigation, vol. 26, no. 1, pp. 49–53, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Gallelli, S. De Fazio, E. Corace, C. De Sarro, C. S. Garcia, and P. De Fazio, “Generalised urticaria in a young woman treated with clomipramine and after ingestion of codfish: a case report,” Pharmacopsychiatry, vol. 39, no. 4, pp. 154–156, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Siniscalchi, L. Gallelli, and G. De Sarro, “Combined topiramate and declorazepam therapy in a patient affected by essential tremor,” Parkinsonism and Related Disorders, vol. 13, no. 2, pp. 129–130, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Gareri, P. De Fazio, A. Cotroneo et al., “Anticholinergic drug-induced delirium in an elderly alzheimer's dementia patient,” Archives of Gerontology and Geriatrics, vol. 44, pp. 199–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Siniscalchi, L. Gallelli, S. De Fazio, and G. De Sarro, “Psychic disturbances associated with sodium valproate plus levetiracetam,” Annals of Pharmacotherapy, vol. 41, no. 3, pp. 527–528, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Gareri, P. De Fazio, L. Gallelli et al., “Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation,” Annals of Pharmacotherapy, vol. 42, no. 3, pp. 434–438, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Gallelli, O. Staltari, C. Palleria, G. De Sarro, and M. Ferraro, “Hepatotoxicity induced by methimazole in a previously health patient,” Current Drug Safety, vol. 4, no. 3, pp. 204–206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Siniscalchi, L. Gallelli, G. Calabrò, G. A. Tolotta, and G. De Sarro, “Phenobarbital/lamotrigine coadministration-induced blood dyscrasia in a patient with epilepsy,” Annals of Pharmacotherapy, vol. 44, no. 12, pp. 2031–2034, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Di Mizio, L. Gallelli, V. Barbieri et al., “Capecitabine-induced, rapid decrease of renal function due to drug dispensing error in a hospital pharmacy,” Journal of Clinical Pharmacology, vol. 51, no. 1, pp. 117–119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Scicchitano, C. Giofrè, C. Palleria et al., “Pharmacovigilance and drug safety 2011 in Calabria (Italy): adverse events analysis,” Journal of Research in Medical Sciences, vol. 17, no. 9, pp. 872–875, 2012. View at Google Scholar
  43. J. M. Dalrymple, L. K. Stamp, J. L. O'Donnell, P. T. Chapman, M. Zhang, and M. L. Barclay, “Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 58, no. 11, pp. 3299–3308, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Seideman, O. Beck, S. Eksborg, and M. Wennberg, “The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis,” British Journal of Clinical Pharmacology, vol. 35, no. 4, pp. 409–412, 1993. View at Google Scholar · View at Scopus
  45. R. Segal, E. Mozes, M. Yaron, and B. Tartakovsky, “The effects of methotrexate on the production and activity of interleukin-1,” Arthritis and Rheumatism, vol. 32, no. 4, pp. 370–377, 1989. View at Google Scholar · View at Scopus
  46. R. Segal, M. Yaron, and B. Tartakovsky, “Methotrexate: mechanism of action in rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 20, no. 3, pp. 190–200, 1990. View at Publisher · View at Google Scholar · View at Scopus
  47. K. W. Tan and Y. K. Tay, “A case of acute methotrexate toxicity,” Annals of the Academy of Medicine Singapore, vol. 40, no. 2, pp. 97–99, 2011. View at Google Scholar · View at Scopus
  48. J. I. Schwartz, N. G. B. Agrawal, P. H. Wong et al., “Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis,” Journal of Clinical Pharmacology, vol. 49, no. 10, pp. 1202–1209, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Honjo, Y. Uwai, and K. Iwamoto, “Inhibitory effect of selective cyclooxygenase-2 inhibitor etoricoxib on human organic anion transporter 3 (hOAT3),” Drug Metabolism Letters, vol. 5, no. 2, pp. 140–137, 2011. View at Google Scholar
  50. A. Karim, D. S. Tolbert, T. L. Hunt, R. C. Hubbard, K. M. Harper, and G. S. Geis, “Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 26, no. 12, pp. 2539–2543, 1999. View at Google Scholar · View at Scopus
  51. S. N. Hartmann, C. M. Rordorf, S. Milosavljev et al., “Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients,” Annals of Pharmacotherapy, vol. 38, no. 10, pp. 1582–1587, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Palleria, A. Di Paolo, C. Giofrè et al., “Pharmacokinetic drug-drug interaction and their implication in clinical management,” Journal of Research in Medical Sciences, 2013. View at Google Scholar
  53. A. N. Colebatch, J. L. Marks, D. M. van der Heijde, and C. J. Edwards, “Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review,” Journal of Rheumatology. Supplement, vol. 90, pp. 62–73, 2012. View at Google Scholar
  54. Arava (Leflunomide), Sanofi-Aventis. UK Summary of product characteristics, September 2009.
  55. EMEA, “EMEA public statement on leflunomide (Arava)—severe and serious hepatic reactions,” London, UK, March 2001, http://www.emea.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500018389.pdf.
  56. R. L. Hill, D. J. Topliss, and P. M. Purcell, “Pancytopenia associated with leflunomide and methotrexate,” Annals of Pharmacotherapy, vol. 37, no. 1, p. 149, 2003. View at Google Scholar · View at Scopus
  57. J. McEwen, P. M. Purcell, R. L. Hill, L. J. Calcino, and C. G. Riley, “The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate,” Pharmacoepidemiology and Drug Safety, vol. 16, no. 1, pp. 65–73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Chan, D. C. Sanders, L. Du, and P. I. Pillans, “Leflunomide-associated pancytopenia with or without methotrexate,” Annals of Pharmacotherapy, vol. 38, no. 7-8, pp. 1206–1211, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Londono, A. M. Santos, P. I. Santos, M. F. Cubidez, C. Guzman, and R. Valle-Oñate, “Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment,” Revista Brasileira de Reumatologia, vol. 52, no. 6, pp. 837–845, 2012. View at Google Scholar
  60. S. W. Lee, H. J. Park, B. K. Kim et al., “Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate,” Arthritis Research & Therapy, vol. 14, no. 5, p. R232, 2012. View at Google Scholar
  61. W. Katchamart, J. Trudeau, V. Phumethum, and C. Bombardier, “Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis,” Annals of the Rheumatic Diseases, vol. 68, no. 7, pp. 1105–1112, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Elsby, L. Fox, D. Stresser et al., “In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate,” European Journal of Pharmaceutical Sciences, vol. 43, no. 1-2, pp. 41–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. A. H. Gerards, R. B. M. Landewé, A. P. A. Prins et al., “Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial,” Annals of the Rheumatic Diseases, vol. 62, no. 4, pp. 291–296, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Sarzi-Puttini, E. D'Ingianna, M. Fumagalli et al., “An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis,” Rheumatology International, vol. 25, no. 1, pp. 15–22, 2005. View at Google Scholar · View at Scopus
  65. L. Fuksa, E. Brcakova, G. Kolouchova et al., “Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats,” Toxicology, vol. 267, no. 1–3, pp. 165–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. J. E. A. Wolff, H. Hauch, J. Kühl, R. M. Egeler, and H. Jürgens, “Dexamethasone increases hepatotoxicity of MTX in children with brain tumors,” Anticancer Research, vol. 18, no. 4B, pp. 2895–2899, 1998. View at Google Scholar · View at Scopus
  67. O. A. Malysheva, M. Wahle, U. Wagner et al., “Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs,” Journal of Rheumatology, vol. 35, no. 6, pp. 979–985, 2008. View at Google Scholar · View at Scopus
  68. M. E. Weinblatt, J. M. Kremer, J. S. Coblyn et al., “Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis,” Arthritis & Rheumatism, vol. 42, pp. 1322–1328, 1999. View at Google Scholar
  69. P. Bird, H. Griffiths, K. Tymms et al., “The SMILE study—safety of methotrexate in combination with leflunomide in rheumatoid arthritis,” The Journal of Rheumatology, vol. 40, no. 3, pp. 228–235, 2013. View at Publisher · View at Google Scholar
  70. J. P. Callen, “Complications and adverse reactions in the use of newer biologic agents,” Seminars in Cutaneous Medicine and Surgery, vol. 26, no. 1, pp. 6–14, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. B. T. Luong, B. S. Chong, and D. M. Lowder, “Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab,” Annals of Pharmacotherapy, vol. 34, no. 6, pp. 743–760, 2000. View at Google Scholar · View at Scopus
  72. H. Zhou, P. R. Mayer, J. Wajdula, and S. Fatenejad, “Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis,” Journal of Clinical Pharmacology, vol. 44, no. 11, pp. 1235–1243, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. M. H. Weisman, L. W. Moreland, D. E. Furst et al., “Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study,” Clinical Therapeutics, vol. 25, no. 6, pp. 1700–1721, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. RoActemra (Tocilizumab), Roche Registration Ltd. Summary of product characteristics, January 2009.
  75. Cimzia (Certolizumab pegol), UCB Inc. US Prescribing information, December 2008.
  76. Simponi (Golimumab), Centocor Ortho Biotech Inc. US Prescribing information, April 2009.
  77. J. Von Kempis, J. Dudler, P. Hasler et al., “Use of abatacept in rheumatoid arthritis,” Swiss Medical Weekly, vol. 142, 2012. View at Google Scholar
  78. B. Dijkmans and A. Gerards, “Cyclosporin in rheumatoid arthritis: monitoring for adverse effects and clinically significant drug interactions,” BioDrugs, vol. 10, no. 6, pp. 437–445, 1998. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Baraldo, G. Ferraccioli, F. Pea, E. Gremese, and M. Furlanut, “Cyclosporine a pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy,” Pharmacological Research, vol. 40, no. 6, pp. 483–486, 1999. View at Publisher · View at Google Scholar · View at Scopus
  80. R. B. Velagapudi, P. A. Noertersheuser, W. M. Awni et al., “Effect of methotrexate coadministration on the pharmacokinetics of adalimumab (Humira, Abbott) following a single intravenous injection,” Arthritis & Rheumatism, vol. 48, p. S141, 2003. View at Google Scholar
  81. Humira (Adalimumab), Abbott Laboratories. US Prescribing information, March 2009.
  82. B. Davies and T. Shaw, “Rituximab pharmacokinetic characteristics are not influenced by combination with methotrexate or cyclophosphamide,” Annals of the Rheumatic Diseases, vol. 63, p. FRI0128, 2004. View at Google Scholar
  83. J. A. Singh, G. A. Wells, R. Christensen et al., “Adverse effects of biologics: a network meta-analysis and cochrane overview,” Cochrane Database of Systematic Reviews, vol. 2, Article ID CD008794, 2011. View at Google Scholar · View at Scopus
  84. A. E. Thompson and P. G. Bashook, “Rheumatologists' recommended patient information when prescribing methotrexate for rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 28, no. 4, pp. 539–545, 2010. View at Google Scholar · View at Scopus
  85. E. N. van Roon, P. M. L. A. van den Bemt, T. L. T. A. Jansen, N. M. Houtman, M. A. F. J. van de Laar, and J. R. B. J. Brouwers, “An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists,” Clinical Therapeutics, vol. 31, no. 8, pp. 1737–1746, 2009. View at Publisher · View at Google Scholar · View at Scopus